Oxidative stress and renal injury with intravenous iron-in patients with chronic kidney disease

Kidney International

Volumn 65, Issue 6, 2004, Pages 2279-2289

  Agarwal, Rajiv ^a   Vasavada, Nina ^b   Sachs, Nadine G ^b   Chase, Shawn ^b  

^a RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

Anemia; Chronic kidney failure; Iron; Malondialdehyde; Oxidative stress; Randomized controlled trial

Indexed keywords

ACETYLCYSTEINE; BIOLOGICAL MARKER; FERRIC HYDROXIDE SUCROSE; GLUTATHIONE DISULFIDE; IRON DERIVATIVE; MALONALDEHYDE; MONOCYTE CHEMOTACTIC PROTEIN 1; SCAVENGER; TRANSFERRIN; UREA;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INFUSION; ENZYMURIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY INJURY; LIPID PEROXIDATION; MALE; OCCULT BLOOD; OPEN STUDY; OXIDATIVE STRESS; PARALLEL DESIGN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TIME; URINARY EXCRETION;

EID: 2442677622     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00648.x     Document Type: Article

References (45)

1. CORESH J, WEI GL, MCQUILLAN G, et al: Prevalence of high blood pressure and elevated serum creatinine level in the United States: Findings from the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 161:1207-1216, 2001
2. HSU CY, MCCULLOCH CE, CURHAN GC: Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: Results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 13:504-510, 2002
3. NISSENSON AR, STROBOS J: Iron deficiency in patients with renal failure. Kidney Int 55 (Suppl 69):S18-S21, 1999
4. VALDERRABANO F, JOFRE R, LOPEZ-GOMEZ JM: Quality of life in end-stage renal disease patients. Am J Kidney Dis 38:443-464, 2001
5. BESARAB A: Iron and cardiac disease in the end-stage renal disease setting. Am J Kidney Dis 34:S18-S24, 1999
6. BESARAB A, FRINAK S, YEE J: An indistinct balance: The safety and efficacy of parenteral iron therapy. J Am Soc Nephrol 10:2029-2043, 1999
7. HAUGEN E, NATH KA: The involvement of oxidative stress in the progression of renal injury. Blood Purif 17:58-65, 1999
8. KLAHR S: Oxygen radicals and renal diseases. Miner Electrolyte Metab 23:140-143, 1997
9. AGARWAL R, WARNOCK D: Issues related to iron replacement in chronic kidney disease. Semin Nephrol 22:479-487, 2002
10. ZAGER RA, JOHNSON AC, HANSON SY, WASSE H: Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 40:90-103, 2002
11. SHAH SV: Role of iron in progressive renal disease. Am J Kidney Dis 37:S30-S33, 2001
12. HANDELMAN GJ, WALTER MF, ADHIKARLA R, et al: Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int 59:1960-1966, 2001
13. SPITTLE MA, HOENICH NA, HANDELMAN GJ, et al: Oxidative stress and inflammation in hemodialysis patients. Am J Kidney Dis 38:1408-1413, 2001
14. SALAHUDEEN AK, OLIVER B, BOWER JD, ROBERTS LJ: Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis. Kidney Int 60:1525-1531, 2001
15. ROOB JM, KHOSCHSORUR G, TIRAN A, et al: Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 11:539-549, 2000
16. DRUEKE T, WITKO-SARSAT V, MASSY Z, et al: Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106:2212-2217, 2002
17. BECKER BN, HIMMELFARB J, HENRICH WL, HAKIM RM: Reassessing the cardiac risk profile in chronic hemodialysis patients: A hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol 8:475-486, 1997
18. TEPEL M, VAN DER GM, SCHWARZFELD C, et al: Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 343:180-184, 2000
19. LEVEY AS, BOSCH JP, LEWIS JB, et al: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group [see comments]. Ann Intern Med 130:461-470, 1999
20. LOOKER AC, DALLMAN PR, CARROLL MD, et al: Prevalence of iron deficiency in the United States. JAMA 277:973-976, 1997
21. IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis 37:S182-S238, 2001
22. WILLIAMS J, EVANS RW, MORETON K: The iron-binding properties of hen ovotransferrin. Biochem J 173:533-539, 1978
23. RAYMAN MP, BARLIS J, EVANS RW, et al: Abnormal iron parameters in the pregnancy syndrome preeclampsia. Am J Obstet Gynecol 187:412-418, 2002
24. PARONI R, DE VECCHI E, CIGHETTI G, et al: HPLC with ophthalaldehyde precolumn derivatization to measure total, oxidized, and protein-bound glutathione in blood, plasma, and tissue. Clin Chem 41:448-454, 1995
25. AGARWAL R, CHASE SD: Rapid, fluorimetric-liquid chromatographic determination of malondialdehyde in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci 775:121-126, 2002
26. PARKKINEN J, VON BONSDORFF L, PELTONEN S, et al: Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant 15:1827-1834, 2000
27. DANIELSON BG, SALMONSON T, DERENDORF H, GEISSER P: Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers. Arzneimittelforschung 46:615-621, 1996
28. SATO K, SHIRAKI M: Saccharated ferric oxide-induced osteomalacia in Japan: Iron-induced osteopathy due to nephropathy. Endocr J 45:431-439, 1998
29. ROOYAKKERS TM, STROES ES, KOOISTRA MP, et al: Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 32 (Suppl 1):9-16, 2002
30. HERRERA J, NAVA M, ROMERO F, RODRIGUEZ-ITURBE B: Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am J Kidney Dis 37:750-757, 2001
31. TOVBIN D, MAZOR D, VOROBIOV M, et al: Induction of protein oxidation by intravenous iron in hemodialysis patients: Role of inflammation. Am J Kidney Dis 40:1005-1012, 2002
32. SENGOELGE G, KLETZMAYR J, FERRARA I, et al: Impairment of transendothelial leukocyte migration by iron complexes. J Am Soc Nephrol 14:2639-2644, 2003
33. FAICH G, STROBOS J: Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextrans. Am J Kidney Dis 33:464-470, 1999
34. YOSHIOKA T, ICHIKAWA I, FOGO A: Reactive oxygen metabolites cause massive, reversible proteinuria and glomerular sieving defect without apparent ultrastructural abnormality. J Am Soc Nephrol 2:902-912, 1991
35. GAILIT J, COLFLESH D, RABINER I, et al: Redistribution and dysfunction of integrins in cultured renal epithelial cells exposed to oxidative stress. Am J Physiol 264:F149-F157, 1993
36. SHAH SV: Evidence suggesting a role for hydroxyl radical in passive Heymann nephritis in rats. Am J Physiol 254:F337-F344, 1988
37. JOHNSON RJ, COUSER WG, CHI EY, et al: New mechanism tor glomerular injury. Myeloperoxidase-hydrogen peroxide-halide system. J Clin Invest 79:1379-1387, 1987
38. NANKIVELL BJ, BOADLE RA, HARRIS DC: Iron accumulation in human chronic renal disease. Am J Kidney Dis 20:580-584, 1992
39. ALFREY AC, FROMENT DH, HAMMOND WS: Role of iron in the tubulointerstitial injury in nephrotoxic serum nephritis. Kidney Int 36:753-759, 1989
40. PATRUTA SI, EDLINGER R, SUNDER-PLASSMANN G, HORL WH: Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 9:655-663, 1998
41. FINCH CA, MILLER LR, INAMDAR AR, et al: Iron deficiency in the rat. Physiological and biochemical studies of muscle dysfunction. J Clin Invest 58:447-453, 1976
42. BRUNER AB, JOFFE A, DUGGAN AK, et al: Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. Lancet 348:992-996, 1996
43. EARLEY CJ, CONNOR JR, BEARD JL, et al: Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology 54:1698-1700, 2000
44. MARTINEZ-TORRES C, CUBEDDU L, DILLMANN E, et al: Effect of exposure to low temperature on normal and iron-deficient subjects. Am J Physiol 246:R380-R383, 1984
45. CHANDRA RK: Reduced bactericidal capacity of polymorphs in iron deficiency. Arch Dis Child 48:864-866, 1973